Clinical Trial Imaging Market Report: Trends, Forecast and Competitive Analysis to 2030

Clinical Trial Imaging Trends and Forecast

The future of the global clinical trial imaging market looks promising with opportunities in the pharmaceutical company, biotechnology company, medical device manufacturer, contract research organization, academic and government research institute markets. The global clinical trial imaging market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.6% from 2024 to 2030. The major drivers for this market are increasing number of CROs, significantly growing pharmaceutical and biotechnology industries, and increasing R&D spending to discover drugs and therapies.

A more than 150-page report is developed to help in your business decisions.

Clinical Trial Imaging by Segment

The study includes a forecast for the global clinical trial imaging by product & services, modality, therapeutic area, end use, and region.

Clinical Trial Imaging Market by Product & Services [Shipment Analysis by Value from 2018 to 2030]:

• Software
• Services

Clinical Trial Imaging Market by Modality [Shipment Analysis by Value from 2018 to 2030]:

• Computed Tomography
• Magnetic Resonance Imaging
• Ultrasound
• Positron Emission Tomography
• X-ray
• Echocardiography

Clinical Trial Imaging Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Infectious Diseases
• Neurology
• CVS
• Endocrinology
• Immunological Disorder

Clinical Trial Imaging Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Manufacturer
• Contract Research Organizations
• Academic and Government Research Institutes
• Others

Clinical Trial Imaging Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Clinical Trial Imaging Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies clinical trial imaging companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the clinical trial imaging companies profiled in this report include-

• Icon
• Biotelemetry
• Medpace Holdings
• Biomedical Systems Corporation
• Bioclinica
• Ixico
• Resonance Health
• Radiant Sage
• Intrinsic Imaging
• Cardiovascular Imaging Technologies

Clinical Trial Imaging Market Insights

Lucintel forecasts that computed tomography will remain the largest segment over the forecast period due to including the increasing presence of contract research organizations (CROs) and rising research and development investments.

Within this market, pharmaceutical companies will remain the largest segment due to increasing demand for new treatments and medications aimed at addressing chronic diseases.

North America is expected to witness highest growth over the forecast period due to the presence of big outsourcing companies and an increase in r&d in the region. various factors such as the increasing geriatric population along with growing chronic diseases are projected to drive the market in north america. north america also performs the maximum number of clinical trials.

Features of the Global Clinical Trial Imaging Market

Market Size Estimates: Clinical trial imaging market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Clinical trial imaging market by various segments, such as by product & services, modality, therapeutic area, end use and region in terms of($B).

Regional Analysis: Clinical trial imaging market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product & services, modalities, therapeutic areas, end uses, and regions for the clinical trial imaging market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the clinical trial imaging market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the clinical trial imaging market size?

Answer: The global clinical trial imaging market is expected to reach an estimated $2.1 billion by 2030.

Q.2 What is the growth forecast for clinical trial imaging market?

Answer: The global clinical trial imaging market is expected to grow with a CAGR of 7.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the clinical trial imaging market?

Answer: The major drivers for this market are increasing number of CROs, significantly growing pharmaceutical and biotechnology industries, and increasing R&D spending to discover drugs and therapies.

Q4. What are the major segments for clinical trial imaging market?

Answer: The future of the clinical trial imaging market looks promising with opportunities in the pharmaceutical company, biotechnology company, medical device manufacturer, contract research organization, academic and government research institute markets.

Q5. Who are the key clinical trial imaging market companies?

Answer: Some of the key clinical trial imaging companies are as follows:

• ICON
• Biotelemetry
• Medpace Holdings
• Biomedical Systems Corporation
• Bioclinica
• IXICO
• Resonance Health
• Radiant Sage
• Intrinsic Imaging
• Cardiovascular Imaging Technologies

Q6. Which clinical trial imaging market segment will be the largest in future?

Answer: Lucintel forecasts that computed tomography will remain the largest segment over the forecast period due to including the increasing presence of contract research organizations (CROs) and rising research and development investments.

Q7. In clinical trial imaging market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the presence of big outsourcing companies and an increase in r&d in the region. various factors such as the increasing geriatric population along with growing chronic diseases are projected to drive the market in north america. north america also performs the maximum number of clinical trials.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the clinical trial imaging market by product & services (software and services), modality (computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, and echocardiography), therapeutic area (oncology, infectious diseases, neurology, CVS, endocrinology, and immunological disorder), end use (pharmaceutical companies, biotechnology companies, medical device manufacturer, contract research organizations, academic and government research institutes, and others),and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?